Drugs / MK-7680
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02269059 | Dec 2014 → Feb 2015 | hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-7680 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02269059 ↗ |
| Route | Oral | “Participants take MK-7680 capsules by mouth once daily (QD) for 7 days.” NCT02269059 ↗ |